Prof Nicholas Short speaks to ecancer about a phase II study of blinatumomab for the treatment of minimal residual disease-positive B-cell acute lymphoblastic leukaemia.
Initially, he describes the rationale of the study. He then discusses the methodology and results of this study.
This study proves that blinatumomab is well-tolerated and highly effective in eradicating the minimal residual disease in patients with B-cell ALL who have persistent MRD or who experience MRD relapse.
In the end, he discusses the impact these results can have on the future treatment of B-cell ALL.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.